Abstract
The Belgian Ministry of Public Health distributes an Independent Drug Formulary (IDF) on a 2-yearly basis. This formulary (called the Gecommentarieerd Geneesmiddelenrepertorium) is edited by a group of prominent experts in pharmacology, brought together by the Belgian Centre for Pharmacotherapeutic Information. It contains scientific information about all drugs marketed in Belgium; it also mentions the brand name, composition, package form, prices per package and reimbursement category. [The NHI reimburses drugs according to their reimbursement category. Drugs of category (a) are totally reimbursed. For pensioners, widows, orphans and invalids, the NHI reimburses 85%, 50% and 40% for drugs of categories (b), (c) and (cs) respectively; for other insured persons, the reimbursement percentages are respectively 75%, 50% and 40%. Drugs of category (d) are not reimbursed.] Daily drug costs and comparisons between those costs for similar therapies are not provided, however. There is also a brief comparison between the relative medical effectiveness of the drugs in similar therapeutic categories; price comparisons are absent, however. This formulary is sent, free of charge, to all Belgian physicians and pharmacists. Students in the last 2 years of their graduate studies also receive a copy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Avorn J, Soumerai S (1983) Improving drug therapy decisions through educational outreach.
A randomized controlled trial of academically based “detailing”. N Engl J Med 308:1457–1463
Babington M, Robinson L, Monson R (1983) Effect of written information on physicians’ knowledge of drug prices. South Econ J 76(3):328–331
Kesenne J, Feltesse P (1988) De Uitgaven van de Ziekteverzekering voor Werknemers van 1945 tot 1986. Dossier 16, Landsbond van Christelijke Mutualiteiten, Brussel, p 96
Lilja J (1976) How physician’s choose their drugs. Soc Sci Med 10:363–365
Lowy DR, Lowy L, Warner RS (1972) A survey of physicians’ awareness of drug costs. J Med Educ 47:349–351
Manning P, Lee P, Clintworth W, Denson T, Oppenheimer P, Gilman N (1986) Changing prescribing practices through individual continuing education. J Am Med Assoc 256(2):230–232
Oppenheim GL, Erickson SH, Ashworth C (1981) The family physician’s knowledge of the cost of prescribed drugs. J Fam Pract 12(6):1027–1030
Schroeder SA, Kenders K, Cooper J, Piemme T (1973) Use of laboratory tests and pharmaceuticals. Variation among physicians and effect of cost audit and subsequent use. J Am Med Assoc 225(8):969–973
Soumerai SB, Avorn J (1984) Efficacy and cost-containment in hospital pharmacotherapy: state of the art and future directions. Milbank Mem Fund Q/Health Soc 62(3):447–474
Zelnio R (1982) Physician’s use of the guide to prescription drug costs: an exploration. Drug Intell Clin Pharm 16:874–875
Zelnio RN, Gagnon JP (1979) The effects of price information on physician prescribing patterns — a literature review. Drug Intell Clin Pharm 13:156–159
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
de Graeve, D., Carrin, G. (1991). Drug Price Information and Cost-Consciousness of Physicians: Results of a Survey of Belgian General Practitioners. In: López-Casasnovas, G. (eds) Incentives in Health Systems. Health Systems Research. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76580-3_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-76580-3_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53933-9
Online ISBN: 978-3-642-76580-3
eBook Packages: Springer Book Archive